# CUZD1

## Overview
The CUZD1 gene encodes the protein CUB and zona pellucida-like domains 1, which is primarily involved in the regulation of mammary gland development and function during pregnancy and lactation. This protein is a key player in the JAK/STAT5 signaling pathway, where it enhances the phosphorylation and nuclear translocation of STAT5, thereby facilitating the expression of genes critical for epithelial proliferation and differentiation. CUZD1 also influences the expression of epidermal growth factor family ligands, which are vital for epithelial cell proliferation. Beyond its role in the mammary gland, CUZD1 is expressed in adipocytes, where it interacts with STAT5A in response to growth hormone, suggesting a role in adipogenesis and hormonal regulation. Clinically, CUZD1 is implicated in various diseases, including inflammatory bowel diseases and cancers, where its expression levels and interactions may serve as potential biomarkers or therapeutic targets (Mapes2017CUZD1; Wigger2024The; Gao2021Genetic).

## Function
The CUZD1 gene encodes a protein that plays a critical role in the development and function of the mammary gland during pregnancy and lactation. It is involved in the JAK/STAT5 signaling pathway, which is essential for mammary gland development. CUZD1 interacts with JAK1/JAK2 and STAT5, enhancing STAT5 phosphorylation and nuclear translocation, which is crucial for prolactin-induced signaling. This interaction facilitates the expression of genes involved in epithelial proliferation and differentiation, such as epiregulin and whey acidic protein (Mapes2017CUZD1).

CUZD1 also influences the expression of epidermal growth factor (EGF) family ligands, including neuregulin-1, epiregulin, and epigen, which activate ErbB1 and ErbB4 receptors. These receptors are important for epithelial cell proliferation and differentiation during alveolar development in the mammary gland (Mapes2017CUZD1).

In adipocytes, CUZD1 is expressed in the nucleus and interacts with STAT5A, particularly in response to growth hormone stimulation. This suggests a role in adipogenesis and hormonal regulation, although its exact function in adipocytes remains less clear (Wigger2024The).

## Clinical Significance
CUZD1 has been implicated in various diseases, particularly in the context of inflammatory bowel diseases (IBD) and cancers. In Crohn's disease (CD), CUZD1 is a significant target of pancreatic autoantibodies, with studies indicating that the presence of anti-CUZD1 antibodies is associated with a higher likelihood of developing perianal complications (Papp2015Rediscovery; Pavlidis2016Diagnostic). These antibodies are more prevalent in CD patients compared to those with ulcerative colitis (UC), suggesting their potential utility in distinguishing between these conditions (Farkona2017Novel).

In hepatocellular carcinoma (HCC), high expression levels of CUZD1 have been linked to poor prognosis, indicating its role in tumor progression (Gao2021Genetic). CUZD1 is also overexpressed in ovarian cancer, where elevated serum levels have been noted, suggesting its potential as a biomarker for this disease (Conrad2014Antipancreatic; Komorowski2013Autoantibodies).

Alterations in CUZD1 expression and its interactions may influence immune responses and disease phenotypes, as seen in its association with autoimmune conditions like CD and its potential involvement in cancer progression (Lopens2020The).

## Interactions
CUZD1 interacts with several proteins, particularly within the JAK/STAT signaling pathway, which is crucial for mammary gland development during pregnancy. It forms a complex with JAK1, JAK2, and STAT5, facilitating the phosphorylation and nuclear translocation of STAT5. This interaction is essential for the activation of STAT5, which regulates the expression of genes involved in mammary epithelial cell proliferation and differentiation (Mapes2017CUZD1). CUZD1 does not directly bind to DNA but is part of a complex with STAT5 that binds to specific regulatory regions of target genes such as Ereg, Wap, and Csn2 (Mapes2017CUZD1).

In adipocytes, CUZD1 is expressed in the nucleus and interacts with STAT5A, with this interaction being enhanced by growth hormone stimulation. This suggests a role in adipocyte biology, particularly in adipogenesis and hormonal regulation (Wigger2024The). The interaction between CUZD1 and STAT5A in adipocytes occurs in the nucleus and is increased upon the translocation of STAT5A to the nucleus in response to growth hormone (Wigger2024The). These interactions highlight CUZD1's involvement in cellular signaling pathways and its potential role in regulating gene expression.


## References


[1. (Conrad2014Antipancreatic) Karsten Conrad, Dimitrios Bogdanos, and Dirk Roggenbuck. Antipancreatic Autoantibodies, pages 433–440. Elsevier, 2014. URL: http://dx.doi.org/10.1016/b978-0-444-56378-1.00051-4, doi:10.1016/b978-0-444-56378-1.00051-4. This article has 0 citations.](https://doi.org/10.1016/b978-0-444-56378-1.00051-4)

[2. (Komorowski2013Autoantibodies) Lars Komorowski, Bianca Teegen, Christian Probst, Karola Aulinger-Stöcker, Christian Sina, Klaus Fellermann, and Winfried Stöcker. Autoantibodies against exocrine pancreas in crohn’s disease are directed against two antigens: the glycoproteins cuzd1 and gp2. Journal of Crohn’s and Colitis, 7(10):780–790, November 2013. URL: http://dx.doi.org/10.1016/j.crohns.2012.10.011, doi:10.1016/j.crohns.2012.10.011. This article has 52 citations.](https://doi.org/10.1016/j.crohns.2012.10.011)

[3. (Pavlidis2016Diagnostic) Polychronis Pavlidis, Lars Komorowski, Bianca Teegen, Christos Liaskos, Andreas L. Koutsoumpas, Daniel S. Smyk, Carlo Perricone, Maria G. Mytilinaiou, Winfried Stocker, Alastair Forbes, and Dimitrios P. Bogdanos. Diagnostic and clinical significance of crohn’s disease-specific pancreatic anti-gp2 and anti-cuzd1 antibodies. Clinical Chemistry and Laboratory Medicine (CCLM), January 2016. URL: http://dx.doi.org/10.1515/cclm-2015-0376, doi:10.1515/cclm-2015-0376. This article has 22 citations.](https://doi.org/10.1515/cclm-2015-0376)

[4. (Farkona2017Novel) Sofia Farkona, Antoninus Soosaipillai, Panagiota Filippou, Christos Liaskos, Dimitrios P. Bogdanos, Eleftherios P. Diamandis, and Ivan M. Blasutig. Novel immunoassays for detection of cuzd1 autoantibodies in serum of patients with inflammatory bowel diseases. Clinical Chemistry and Laboratory Medicine (CCLM), January 2017. URL: http://dx.doi.org/10.1515/cclm-2016-1120, doi:10.1515/cclm-2016-1120. This article has 7 citations.](https://doi.org/10.1515/cclm-2016-1120)

5. (Wigger2024The) The Association of CUZD1 and STAT5 in Adipocytes. This article has 0 citations.

[6. (Lopens2020The) Steffi Lopens, Marcin Krawczyk, Maria Papp, Piotr Milkiewicz, Peter Schierack, Yudong Liu, Ewa Wunsch, Karsten Conrad, and Dirk Roggenbuck. The search for the holy grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia. Autoimmunity Highlights, March 2020. URL: http://dx.doi.org/10.1186/s13317-020-00129-x, doi:10.1186/s13317-020-00129-x. This article has 8 citations.](https://doi.org/10.1186/s13317-020-00129-x)

[7. (Gao2021Genetic) Xingjie Gao, Chunyan Zhao, Nan Zhang, Xiaoteng Cui, Yuanyuan Ren, Chao Su, Shaoyuan Wu, Zhi Yao, and Jie Yang. Genetic expression and mutational profile analysis in different pathologic stages of hepatocellular carcinoma patients. BMC Cancer, July 2021. URL: http://dx.doi.org/10.1186/s12885-021-08442-y, doi:10.1186/s12885-021-08442-y. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-021-08442-y)

[8. (Mapes2017CUZD1) Janelle Mapes, Quanxi Li, Athilakshmi Kannan, Lavanya Anandan, Mary Laws, John P. Lydon, Indrani C. Bagchi, and Milan K. Bagchi. Cuzd1 is a critical mediator of the jak/stat5 signaling pathway that controls mammary gland development during pregnancy. PLOS Genetics, 13(3):e1006654, March 2017. URL: http://dx.doi.org/10.1371/journal.pgen.1006654, doi:10.1371/journal.pgen.1006654. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1006654)

[9. (Papp2015Rediscovery) Maria Papp, Nora Sipeki, Tamas Tornai, Istvan Altorjay, Gary L. Norman, Zakera Shums, Dirk Roggenbuck, Kai Fechner, Winfried Stöcker, Peter Antal-Szalmas, Gabor Veres, and Peter Laszlo Lakatos. Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of crohn’s patients: the importance of specific target antigens [gp2 and cuzd1]. Journal of Crohn’s and Colitis, 9(8):659–668, May 2015. URL: http://dx.doi.org/10.1093/ecco-jcc/jjv087, doi:10.1093/ecco-jcc/jjv087. This article has 39 citations.](https://doi.org/10.1093/ecco-jcc/jjv087)